Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database

Part of paid clinical trials in Princeton, New Jersey.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07079644
Status
Completed

Conditions

  • Advanced Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab + Relatlimab — BIOLOGICAL
    As per product label
  • Nivolumab + Ipilimumab — BIOLOGICAL
    As per product label
  • Immunotherapy monotherapy — BIOLOGICAL
    As per product label
  • BRAF/MEK inhibitors — DRUG
    As per product label

Study Details

The purpose of this study is to investigate the real-world clinical outcomes of individuals that have been diagnosed with advanced melanoma who were treated with Nivolumab in combination with Relatlimab, Nivolumab in combination with Ipilimumab, immuno-oncology monotherapy or BRAF/MEK inhibitors therapy

Key Dates

First listed
Jul 23, 2025
Start date
Nov 29, 2024
Status verified
Jul 2025
Primary completion
Mar 31, 2025
Completion
Mar 31, 2025

Study Design

Enrollment
678 participants (actual)

Arms

  • Arm: 1L Nivolumab + Relatlimab cohort
  • Arm: 1L Nivolumab + Ipilimumab cohort
  • Arm: 1L Immunotherapy monotherapy cohort
  • Arm: 1L BRAF/MEKs inhibitors cohort

Primary Outcome Measure

Demographics [ Time Frame: Baseline ]

Locations (1)

FacilityCityStateZIPSite coordinators
Bristol Myers SquibbPrincetonNew Jersey08540-4715-

Find similar trials in Princeton, NJ

By research site
Bristol Myers Squibb· Princeton, NJ

Related Studies